摘要
目的探讨红玉赔赈颗粒对脓毒症患者血白细胞计数(WBC)、中性粒细胞百分比(N%)、超敏C反应蛋白(hs-CRP)、红细胞沉降率(ESR)、血清降钙素原(PCT)、动脉血乳酸(Lac)炎症指标的干预作用。方法将70例符合脓毒症诊断标准的急危重病症患者随机分为2组,试验组在西医常规治疗的基础上予以连续7 d口服或鼻饲红玉赔赈颗粒,对照组在西医常规治疗组基础上加用1/10的红玉赔赈颗粒安慰剂,检测2组患者治疗前以及治疗后第1天、第3天、第7天的血清WBC、N%、hs-CRP、ESR、Pct、动脉血Lac水平。结果与对照组比较,治疗后第7天试验组N%、hs-CRP、ESR、PCT、动脉血Lac指标水平均降低更显著(P <0. 05)。结论红玉赔赈颗粒能对脓毒症患者炎症反应起抑制作用,可改善脓毒症患者因组织缺氧及低灌注所致的高乳酸血症,从而改善预后。
Objective To investigate effect of Hongyu Peizhen Granule on inflammatory indicators such as white blood cell( WBC),neutrophil percentage( N%),hypersensitive C reaction protein( hs-CRP),erythrocyte sedimentation rate( ESR),serum procalcitonin( PCT),arterial blood lactic acid( Lac) in sepsis patients. Methods Seventy acute and critical illness patients in accordance with the diagnostic criteria of sepsis were randomly divided into two groups. The patients of two groups were all given routine western medicine treatment,the experimental group was orally or nasally given Hongyu Peizhen Granule for 7 consecutive days in addition,while the control group additionally received 1/10 dose of Hongyu Peizhen Granule as placebo. The serum levels of WBC,N%,hs-CRP,ESR,PCT and Lac in arterial blood before treatment,and at 1,3,7 d after treatment were measured. Results Compared with the control group,the levels of N%,hs-CRP,ESR,PCT,arterial blood Lac at 7 d in the experimental group decreased more significantly( P < 0. 05). Conclusion Hongyu Peizhen Granule can inhibit the inflammatory reaction of sepsis patients and improve their hyperlacticemia caused by tissue hypoxia and hypoperfusion thereby improving the prognosis of sepsis patients.
引文
[1] Singer M,Deutschman C S,Seymour C W,et al. The third international consensus definitions for sepsis and septic shock(sepsis-3)[J]. JAMA,2016,315(8):801-810.
[2] Rhodes A,Evans L E,Alhazzani W,et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J]. Crit Care Med,2017,45(3):486-552.
[3]中国中西医结合学会急救医学专业委员会,《中国中西医结合急救杂志》编辑委员会.脓毒症中西医结合诊治专家共识[J].中华危重病急救医学,2013,25(4):194-197.
[4]中华医学会急诊医学分会危重病专家委员会,中国中西医结合学会急救医学专业委员会.脓毒症的定义、诊断标准、中医证候诊断要点及说明(草案)[J].中华急诊医学杂志,2007,16(8):797-798.
[5]郑筱英.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:87-88.
[6]钟嘉熙.温病学(案例版)[M].北京:科学出版社,2007:102-103.
[7] Martin G S,Mannino D M,Eaton S,et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med,2003,348(16):1546-1554.
[8] Linde-Zwirble W T,Angus D C. Severe sepsis epidemiology:sampling,selection,and society[J]. Crit Care,2004,8(4):222-226.
[9] Dombrovskiy V Y,Martin A A,Sunderram J,et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States:a trend analysis from 1993 to 2003[J].Crit Care Med,2007,35(5):1244-1250.
[10]高斌,李仁柱,朱亮,等.升降散对初期脓毒症患者中医症候的干预研究[J].辽宁中医药大学学报,2009,11(12):100-102.
[11]夏一春,钱风华,奚耀,等.升降散对脓毒症大鼠肾功能的影响[J].上海中医药大学学报,2013,27(2):77-80.
[12]钟赣生.中药学[M].北京:中国中医药出版社,2012:378-379.